Home > Healthcare > Drug Device Combination > Therapeutic Systems > Radiotherapy Induced Oral Mucositis Treatment Market

Radiotherapy Induced Oral Mucositis Treatment Market Size

  • Report ID: GMI9225
  • Published Date: Apr 2024
  • Report Format: PDF

Radiotherapy Induced Oral Mucositis Treatment Market Size

Radiotherapy Induced Oral Mucositis Treatment Market size was valued at around USD 2.5 billion in 2023 and is estimated to grow at 4.4% CAGR from 2024 to 2032, driven by the increasing incidence of cancer necessitating radiotherapy coupled with advancements in radiotherapy techniques and a growing focus on supportive care.

 

According to the latest estimates from the International Agency for Research on Cancer (IARC) in 2022, there were approximately 20 million new cancer cases projecting a rise of over 35 million new cancer cases that by 2050, reflecting a substantial 77% increase from the estimated cases in 2022. Therefore, the increasing prevalence of cancer elevates the demand for cancer treatments such as radiotherapy, consequently boosting the need for remedies targeting oral mucositis and propelling market expansion.
 

Radiotherapy induced oral mucositis treatment refers to therapeutic interventions aimed at managing and alleviating the adverse effects of oral mucositis induced by radiotherapy. This condition characterized by inflammation, ulceration, and pain in the oral mucosa, commonly occurs as a side effect of radiation therapy for head and neck cancer or other types of cancers.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The radiotherapy induced oral mucositis treatment market was valued at USD 2.5 billion in 2023 and is estimated to grow at 4.4% CAGR from 2024 to 2032, driven by the increasing incidence of cancer coupled with advancements in radiotherapy techniques.

The medication segment in the radiotherapy induced oral mucositis treatment industry is anticipated to reach USD 2.3 billion by end of 2032, due to its widespread adoption and effectiveness in treating various conditions.

North America radiotherapy induced oral mucositis treatment market size generated USD 864.4 million in 2023, attributed to its advanced healthcare infrastructure, significant investments in the oncology field, and a high prevalence of cancer cases.

Amgen Inc., Aurora BioScience, Colgate-Palmolive Company, Galera Therapeutics, Enzychem Lifesciences Corporation, EpicentRx, Izun Pharmaceuticals, MuReva Phototherapy Inc., Solasia Pharma K.K. and Soligenix Inc.

Radiotherapy Induced Oral Mucositis Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 401
  • Countries covered: 22
  • Pages: 190
 Download Free Sample